Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So when we looked at Elevance Health (NYSE:ELV) and its trend of ROCE, we really liked what we saw.
尋找一個有潛力大幅增長的業務並不容易,但只要我們看幾個關鍵的財務指標就有可能。理想情況下,一個業務應該呈現出兩個趨勢;首先是不斷增長的資本採用回報率(ROCE),其次是日益增加的資本採用量。這表明它是一個複利機器,能夠不斷將收益再投資到業務中並獲得更高的回報。因此,當我們看到Elevance Health(NYSE:ELV)及其ROCE的趨勢時,我們非常喜歡我們所看到的。
Understanding Return On Capital Employed (ROCE)
上面您可以看到蒙托克可再生能源現行ROCE與之前資本回報的比較,但過去只能知道這麼多。如果您感興趣,可以查看我們免費的蒙托克可再生能源分析師報告,了解分析師的預測。
If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. The formula for this calculation on Elevance Health is:
如果您以前沒有使用過ROCE,它衡量的是公司從其業務中使用的資本所產生的「回報」(稅前利潤)。對於Elevance Health,這個計算公式是:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
資產僱用回報率(ROCE)是指企業利潤,即企業稅前利潤除以企業投入的總資本(負債加股權)。如果ROCE高於企業財務成本的承受能力,那麼企業就會創造出更多的價值。
0.15 = US$11b ÷ (US$113b - US$42b) (Based on the trailing twelve months to June 2024).
0.15 = US$110 billion ÷ (US$113 billion - US$42 billion)(基於截至2024年6月的過去12個月數據)。
Therefore, Elevance Health has an ROCE of 15%. On its own, that's a standard return, however it's much better than the 10% generated by the Healthcare industry.
因此,Elevance Health的ROCE爲15%。單獨看來,這是一個標準的回報率,但遠遠好於醫療保健行業的10%。
In the above chart we have measured Elevance Health's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Elevance Health .
在上面的圖表中,我們對Elevance Health的先前ROCE進行了測量,並將其與先前的業績進行了比較,但未來可能更重要。如果您想了解分析師對未來的預測,請查看我們免費的Elevance Health分析師報告。
What The Trend Of ROCE Can Tell Us
儘管如此,當我們看 enphase energy (納斯達克股票代碼:ENPH) 的時候,它似乎並沒有完全符合這些要求。
The trends we've noticed at Elevance Health are quite reassuring. The data shows that returns on capital have increased substantially over the last five years to 15%. The amount of capital employed has increased too, by 35%. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed.
我們在Elevance Health發現的趨勢相當令人 geratney。數據顯示,過去五年內資本回報率大幅增長至15%。所投入的資本也增加了35%。在不斷增長的資本數量上實現回報率的增加在多倍增長者中很常見,這正是我們的印象所在。
In Conclusion...
最後,同等資本下回報率較低的趨勢通常不是我們關注創業板股票的最佳信號。由於這些發展進行良好,因此投資者不太可能表現友好。自五年前以來,該股下跌了32%。除非這些指標朝着更積極的軌跡轉變,否則我們將繼續尋找其他股票。
A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what Elevance Health has. And a remarkable 136% total return over the last five years tells us that investors are expecting more good things to come in the future. Therefore, we think it would be worth your time to check if these trends are going to continue.
一家能夠增加資本回報率並始終能夠持續投資於自身的公司是非常受追捧的特質,而Elevance Health正具備這一特質。在過去五年內,總回報率達到了驚人的136%,這告訴我們投資者期待未來會有更多好事發生。因此,我們認爲查看這些趨勢是否會持續發展將是值得您花時間去做的。
While Elevance Health looks impressive, no company is worth an infinite price. The intrinsic value infographic for ELV helps visualize whether it is currently trading for a fair price.
雖然Elevance Health看起來令人印象深刻,但沒有任何一家公司值得付出無限的代價。ELV的內在價值信息圖可以幫助您直觀地判斷其當前是否以公平的價格交易。
If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.
如果您想尋找財務狀況良好、回報卓越的實力強企業,可以免費查看以下公司列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。